A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HY6725 Following Single and Multiple Subcutaneous Doses in Healthy Participants
Latest Information Update: 12 Dec 2025
At a glance
- Drugs HY 6725 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Newsoara Biopharma
Most Recent Events
- 12 Dec 2025 New trial record